Efficacy and Safety of MEDI3506 in Adult Subjects with Atopic Dermatitis
Study identifier:D9182C00001
ClinicalTrials.gov identifier:NCT04212169
EudraCT identifier:2019-003304-12
CTIS identifier:N/A
Study Complete
Official Title
A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects with Moderate-to-severe Atopic Dermatitis
Medical condition
Atopic Dermatitis
Phase
Phase 2
Healthy volunteers
No
Study drug
MEDI3506, Placebo
Sex
All
Actual Enrollment
148
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 09 Dec 2019
Primary Completion Date: 21 Jul 2022
Study Completion Date: 20 Sept 2022
Study design
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verification:
Verified 01 Aug 2023 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: MEDI3506 at dose level 1 Participant will receive multiple doses of MEDI3506 at dose level 1. | Drug: MEDI3506 multiple doses |
| Experimental: MEDI3506 at dose level 2 Participant will receive multiple doses of MEDI3506 at dose level 2. | Drug: MEDI3506 multiple doses |
| Experimental: MEDI3506 at dose level 3 Participant will receive multiple doses of MEDI3506 at dose level 3. | Drug: MEDI3506 multiple doses |
| Placebo Comparator: Placebo Participant will receive multiple doses of Placebo | Drug: Placebo multiple doses |
